CN103097404B - 具有镇痛作用并抑制asic通道的新型肽 - Google Patents

具有镇痛作用并抑制asic通道的新型肽 Download PDF

Info

Publication number
CN103097404B
CN103097404B CN201180043328.6A CN201180043328A CN103097404B CN 103097404 B CN103097404 B CN 103097404B CN 201180043328 A CN201180043328 A CN 201180043328A CN 103097404 B CN103097404 B CN 103097404B
Authority
CN
China
Prior art keywords
peptide
pain
asicalgin
asic
passage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180043328.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN103097404A (zh
Inventor
埃里克·林古艾格利亚
西尔维·狄奥舒特
安妮·巴伦-福斯特
米格尔·萨利纳斯
米歇尔·拉兹敦斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NATIONAL CENTER FOR SCIENTIFIC RESEARCH
Original Assignee
NATIONAL CENTER FOR SCIENTIFIC RESEARCH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NATIONAL CENTER FOR SCIENTIFIC RESEARCH filed Critical NATIONAL CENTER FOR SCIENTIFIC RESEARCH
Publication of CN103097404A publication Critical patent/CN103097404A/zh
Application granted granted Critical
Publication of CN103097404B publication Critical patent/CN103097404B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201180043328.6A 2010-07-26 2011-07-26 具有镇痛作用并抑制asic通道的新型肽 Active CN103097404B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1003136A FR2963010B1 (fr) 2010-07-26 2010-07-26 Nouveaux peptides avec des effets analgesiques et inhibant les canaux asic
FR1003136 2010-07-26
PCT/FR2011/051800 WO2012022894A1 (fr) 2010-07-26 2011-07-26 Nouveaux peptides avec des effets analgesiques et inhibant les canaux asic

Publications (2)

Publication Number Publication Date
CN103097404A CN103097404A (zh) 2013-05-08
CN103097404B true CN103097404B (zh) 2015-09-16

Family

ID=43589927

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180043328.6A Active CN103097404B (zh) 2010-07-26 2011-07-26 具有镇痛作用并抑制asic通道的新型肽

Country Status (13)

Country Link
US (1) US8987207B2 (enExample)
EP (1) EP2598523B1 (enExample)
JP (1) JP6000245B2 (enExample)
CN (1) CN103097404B (enExample)
AU (1) AU2011290589A1 (enExample)
BR (1) BR112013001863A2 (enExample)
CA (1) CA2806471C (enExample)
FR (1) FR2963010B1 (enExample)
MX (1) MX336586B (enExample)
RU (1) RU2583299C2 (enExample)
SG (1) SG187877A1 (enExample)
WO (1) WO2012022894A1 (enExample)
ZA (1) ZA201300662B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105233286B (zh) * 2015-09-10 2018-10-30 上海交通大学医学院 含酸敏感离子通道调控剂的制剂及其在治疗瘙痒中的用途
CN105412932B (zh) * 2015-10-26 2019-08-16 上海交通大学医学院 含ASIC1a与RIP1结合抑制剂的制剂及其抑制神经元死亡的用途
CN112717135A (zh) * 2016-11-22 2021-04-30 上海交通大学医学院 酸敏感离子通道调控剂的用途
CN107384952A (zh) * 2017-08-23 2017-11-24 湖南甲骨文生物医药有限公司 用于筛选ASICs作用蛋白的酵母双杂交诱饵载体的构建方法
KR20220016891A (ko) * 2019-06-04 2022-02-10 상하이테크 유니버시티 친화성-성숙된 항-ASIC1a 항체
RU2768484C1 (ru) * 2021-05-24 2022-03-24 Закрытое акционерное общество "СКАЙ ЛТД" Фармацевтическая композиция иммуностимулирующих веществ мурамилпептидной природы

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776896A (en) 1996-01-03 1998-07-07 Zeneca Limited Analgesic peptides from venom of grammostola spatulata and use thereof
JP4959226B2 (ja) * 2006-05-19 2012-06-20 独立行政法人産業技術総合研究所 スリーフィンガー様蛋白質ライブラリ
JP2008193923A (ja) * 2007-02-09 2008-08-28 Janusys Kk 蛋白質ライブラリ

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cloning and purification of alpha-neurotoxins from king cobra (Ophiophagus hannah);HE YING-YING ET AL;《TOXICON》;20040901;第44卷(第3期);295-303 *
Isolation of a tarantula toxin specific for a class of proton-gated Na+ channels;ESCOUBAS ET AL;《JOURNAL OF BIOLOGICAL CHEMISTRY》;20000818;第275卷(第33期);25116-25121 *

Also Published As

Publication number Publication date
JP6000245B2 (ja) 2016-09-28
RU2583299C2 (ru) 2016-05-10
EP2598523A1 (fr) 2013-06-05
US8987207B2 (en) 2015-03-24
SG187877A1 (en) 2013-03-28
US20130196923A1 (en) 2013-08-01
WO2012022894A4 (fr) 2012-04-12
FR2963010A1 (fr) 2012-01-27
CN103097404A (zh) 2013-05-08
CA2806471A1 (fr) 2012-02-23
ZA201300662B (en) 2013-09-25
BR112013001863A2 (pt) 2016-05-31
JP2013535965A (ja) 2013-09-19
WO2012022894A1 (fr) 2012-02-23
AU2011290589A1 (en) 2013-03-07
MX2013001020A (es) 2014-04-14
FR2963010B1 (fr) 2014-08-15
EP2598523B1 (fr) 2015-09-09
RU2013108262A (ru) 2014-09-10
CA2806471C (fr) 2020-07-07
MX336586B (es) 2016-01-21

Similar Documents

Publication Publication Date Title
JP3273792B2 (ja) Ｎｍｄａレセプターのアロステリックモジュレーター
CN103097404B (zh) 具有镇痛作用并抑制asic通道的新型肽
US6277825B1 (en) Use of conantokins for treating pain
WO2013142229A1 (en) Designing novel peptides for inducing fibronectin matrix assembly
KR20170104457A (ko) 신경변성 장애
EP0648269A1 (fr) Nouveaux polypeptides ayant une activite de recepteur nmda, acides nucleiques codant pour ces polypeptides et utilisations
EP2561886A1 (en) Peptide adjuvant for improved peripheral analgesia
AU3886497A (en) Use of conantokins
KR101293777B1 (ko) 알러지성 질환의 치료 및 예방을 위한 펩타이드
US6399574B1 (en) Use of conantokins
JP6818215B2 (ja) クモ毒ペプチド由来の神経保護剤
US20030194729A1 (en) Conantokins
EP1765851B1 (en) Analog compounds of analgesic peptides derived from the venom of crotalus durissus terrificus snakes, their uses, compositions, methods of preparation and purification
US10894811B2 (en) Peptide inhibitors of calcium channels
US7202211B2 (en) Methods of preventing or treating brain ischemia or brain injury
US20150252074A1 (en) Antagonist for (Pro)Renin Receptor for the Treatment of Hypertension and Diabetes
US9670250B2 (en) Alpha-helical peptidomimetic inhibitors and methods using same
JP2002526097A (ja) 新規なぺプチド類
Class et al. Patent application title: ANTAGONIST FOR (PRO) RENIN RECEPTOR FOR THE TREATMENT OF HYPERTENSION AND DIABETES Inventors: Yumei Feng (Fort Collins, CO, US)
JPH1121298A (ja) 知覚過敏抑制ペプチド

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant